Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma

Belge, Gazanfer; Grobelny, Francesca; Matthies, Cord; Radtke, Arlo; Dieckmann, Klaus‐Peter

doi:10.21873/invivo.11757

Cited by 33 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study from Nappi et al [15] investigating the use of plasma miR-375 in combination with miR-371a-3p reported optimistic results, with an area under the ROC curve of 0.95 and 0.77 in the discovery and validation sets, respectively. However, several studies examining miR-375 alone in the context of teratoma have found no utility [7,16,17]. Our group confirmed these results and also found no serum miRNAs predictive for teratoma by small RNA sequencing [18].…”

supporting

confidence: 83%

The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors

et al. 2021

View full text Add to dashboard Cite

supporting

confidence: 83%

The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors

et al. 2021

View full text Add to dashboard Cite

“…However, teratoma does not express miR‐371a‐3p 22 . Although miR‐375 was reported to be present in teratoma, 24 Belge et al 25 reported that serum miR‐375‐3p levels of patients with teratoma were not different from those of patients with GCT or controls. Further microarray studies to search for novel markers for teratoma are required.…”

Section: Discussionmentioning

confidence: 98%

Advanced germ cell tumor patients undergoing post‐chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis

et al. 2021

View full text Add to dashboard Cite

Objectives To evaluate the histologic findings and clinical outcomes of post‐chemotherapy retroperitoneal lymph node dissection for advanced germ cell tumor. Methods We analyzed the medical records of 66 patients who underwent post‐chemotherapy retroperitoneal lymph node dissection between 2005 and 2019 at Tsukuba University Hospital. Results The proportions of necrosis, teratoma, and viable germ cell tumor in the specimens were 62.1%, 36.4%, and 1.5%, respectively. The 5‐year progression‐free and overall survival rates were 82.3% and 91.3%, respectively. The 5‐year overall survival rate of patients with residual teratoma was significantly worse than that of patients with necrosis only (74.1% vs 100%). Overall, three patients died: one from cancer and two from teratoma with somatic‐type malignancy. Of these, two patients relapsed after incomplete resection of residual teratoma. When limited to patients with completely resected teratoma, the 5‐year overall survival rate was 91.7%, which did not differ from that for patients with necrosis only. Multivariate analysis showed that presence of teratoma in the primary site and decrease in retroperitoneal lymph node mass to less than 50% of the initial tumor size were independent factors for residual teratoma. However, the absence of these factors could not reliably predict necrosis only in retroperitoneal lymph node dissection specimens. Conclusions In our series, 98% of post‐chemotherapy retroperitoneal lymph node dissection pathology was either necrosis or teratoma, with viable germ cell tumor only found in 2% of patients. Residual teratoma was associated with poorer prognosis, especially in cases of incomplete resection.

show abstract

“…Belge et al reported about serum miR375 in 21 patients with teratoma, 12 patients with other GCT, and 12 control samples (67). The levels of miR375 were not different between teratoma and other GCT patients or controls.…”

Section: Limitations Of Mir371mentioning

confidence: 97%

Narrative review of developing new biomarkers for decision making in advanced testis cancer

Nappi

Nichols²,

Kollmannsberger

2021

Transl Androl Urol

View full text Add to dashboard Cite

Management of testicular germ cell tumor (GCT) patients is based on clinical determinants, mainly CT scan and serum tumor markers (alpha-fetoprotein, beta subunit of HCG and LDH). Treatment decisions are usually straightforward for patients with clear evidence of metastatic disease, confirmed either by imaging tests or by unequivocal elevated tumor markers. However, there are several clinical scenarios where the assessment of metastatic disease is complicated by the limited specificity of the current imaging tests and serum tumor markers. These include patients with clinical stage IIA GCT with negative tumor markers and patients with post-chemotherapy residual disease where, in absence of clear indicators of GCT,decision making and patient treatment allocation become challenging. Therefore, more accurate biomarkers are critical to reduce the risk of under-or over-treatment and to always deliver the most optimal therapy. The objectives of this narrative review are to review the available publications about micro-RNAs in GCT s and their potential clinical applications. Two clusters of micro-RNAs, miR-371a-3p and miR-302/367, specifically expressed by both seminoma and non-seminoma GCT and easily detectable in the peripheral blood, have demonstrated to be promising in this endeavor. Large prospective trials are ongoing to define the operating characteristics of these biomarkers and their clinical utility to improve GCT patient management and reduce the error rate deriving from clinical uncertainty, therefore reducing the risk of sub-optimal treatments.

show abstract

Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma

Cited by 33 publications

References 22 publications

The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors

The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors

Advanced germ cell tumor patients undergoing post‐chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis

Narrative review of developing new biomarkers for decision making in advanced testis cancer

Contact Info

Product

Resources

About